Background Although epicardial coronary arteries dilate in response to changes in flow, the mechanisms responsible for this and the mechanical stimuli that are sensed by the endothelium are not completely defined. We performed the present study to determine the importance of nitric oxide in eliciting epicardial dilation to sustained changes in mean flow and pulse frequency in the coronary circulation of conscious dogs.
Background Although epicardial coronary arteries dilate in response to changes in flow, the mechanisms responsible for this and the mechanical stimuli that are sensed by the endothelium are not completely defined. We performed the present study to determine the importance of nitric oxide in eliciting epicardial dilation to sustained changes in mean flow and pulse frequency in the coronary circulation of conscious dogs.
Methods and Results Dogs were chronically instrumented with a circumflex coronary occluder, piezoelectric crystals to measure epicardial diameter, and a coronary artery catheter placed distal to the crystals for intracoronary drug infusion. Studies were conducted in dogs in the conscious state. We inhibited nitric oxide production by administering the arginine analog Nw-nitro-L-arginine methyl ester (L-NAME, 10 mg/kg IV), which attenuated the epicardial artery diameter changes to left atrial infusions of acetylcholine (10 .g/min) from 140±23 (±SEM) to 46+20 ,um (P<.05). Epicardial dilation to sustained increases in mean coronary flow was examined by infusing adenosine into the distal coronary artery at a constant heart rate. Intracoronary adenosine increased mean flow to the same extent (180±+21 versus 177±24 mL/min after R eactive dilation of epicardial coronary conduit arteries occurs in response to vasodilation of the distal coronary vascular bed in animalsl-4 as well as in conscious humans. 5 The extent of epicardial dilation is both flow and endothelium dependent. It can be prevented by maintaining flow constant2,3 in the face of distal coronary vasodilation. In addition, it is abolished by removing the endothelium in vivo. 6 The latter observation is compatible with the notion that there are one or more endothelium-dependent relaxing factors that locally dilate arteries in response to changes in either intraluminal flow or vessel wall shear stress. 7 Recent studies have demonstrated that endotheliumdependent vasodilation to changes in flow also occurs in isolated coronary resistance vessels.8 Flow-mediated vasodilation of porcine arterioles can be completely abolished by inhibiting nitric oxide production with the arginine analog L-nitro-monomethyl arginine (L-NMMA).9 The role of nitric oxide in flow-mediated vasodilation of coronary conduit arteries is less clear. Chu et al10 found that the peak reactive epicardial coronary dilation to a tran-sient flow increase produced by a 20-second coronary occlusion was attenuated but not completely abolished by inhibiting nitric oxide production with L-NMMA. Studies examining sustained increases in steady flow in cerebral conduit arteries have found that L-NMMA as well as a variety of other antagonists had no effect on flow-mediated vasodilation.1" These disparate results coupled with the observation that the time course of reactive epicardial coronary dilation is substantially longer than the reactive hyperemic flow responsel-4 raise the hypothesis that different mechanisms may be responsible for flow-mediated vasodilation in coronary resistance and conduit vessels. Alternatively, reactive dilation to changes in steady flow and pulse frequency or amplitude may be effected through different mechanisms.
The purpose of the present study was to determine the role of nitric oxide production as a mechanism of flow-dependent vasodilation of large epicardial conduit arteries in vivo. To avoid potentially confounding effects of anesthesia, the studies were conducted in conscious chronically instrumented dogs using ultrasonic crystals to measure epicardial coronary artery diameter. Inhibition of nitric oxide synthesis was achieved by administering the L-arginine analog N'-nitro-L-arginine methyl ester (L-NAME) and confirmed by demonstrating attenuation of the receptor-mediated epicardial vasodilation to acetylcholine. The The crystals were attached to the adventitia of the left circumflex artery distal to the hydraulic occluder. Care was taken to place them so that they were orthogonal to the long axis of the vessel and measured the major diameter. A small Teflon angiocath (connected to polyethylene tubing) was placed into the circumflex artery for drug infusion.14 The catheter was placed so that its tip was at least 3 cm distal to the ultrasonic crystals. A Teflon angiocath was also placed into the pulmonary artery for systemic drug infusion. At the conclusion of instrumentation, the chest was closed, and the pneumothorax was evacuated. The catheters and wires were exteriorized through the chest wall and placed in a jacket that the animal was trained to wear. Animals were given prophylactic antibiotics (300 mg streptomycin and 300 000 U procaine penicillin IM) for 3 to 5 days postoperatively. Postoperative analgesia (2 mg butorphanol IM PRN) was administered until the animals were free of subjective signs of discomfort. Fluid-filled catheters were flushed with saline at regular intervals and filled with heparin (1000 U/mL). Enteric-coated aspirin was begun on the third to fifth postoperative day (325 mg PO QD). The animals were allowed to recover for at least 2 weeks before experiments were conducted in the unanesthetized state.
Experimental Protocols
On the day of the study, the animals were sedated with Innovar-Vet (1 to 3 mL IM). They were placed in a sling and allowed to adjust to the laboratory for 60 minutes before beginning measurements. A demand pacemaker was set at the control heart rate of each animal to prevent reductions in heart rate during the various experimental interventions.
Effect of L-NAME on Epicardial Artery Dilation to Acetylcholine
In seven of the nine animals, we examined the effects of L-NAME on acetylcholine-induced vasodilation of the epicardial coronary artery. Acetylcholine (10 ,ug/mL saline) was infused into the left atrium at continuous rates of 5, 10, and 15 ,g/min. These systemic infusion rates were chosen because they produced significant agonist-induced vasodilation of the (Fig 1, top) . Once coronary flow and diameter had returned to resting values, adenosine (0.5 mg/mL of saline) was infused through the distal coronary artery at 0.5 mg/min to produce sustained coronary vasodilation (Fig 1,  bottom In five of the animals, we determined the effects of pulmonary artery infusion of adenosine on coronary flow and diameter to exclude the possibility that adenosine infused into the distal circumflex artery recirculated and reached significant concentrations in the systemic arterial circulation. Adenosine (0.5 mg/min) was infused into the pulmonary artery, and measurements of coronary flow and diameter were compared with the preinfusion control values. In four of the animals, we were able to examine the effects of intracoronary adenosine infusion when coronary flow was restricted to values that were within 10% of the mean resting flow levels to exclude the 
DNTG-DRest where D is steady-state diameter during an intervention under control conditions or after L-NAME, DRe,, is resting diameter under control conditions or after L-NAME, and DNTG is maximum diameter during nitroglycerin infusion after L-NAME.
Data are presented as the mean±SEM. The constancy of systemic hemodynamics during interventions was assessed by a repeated-measures ANOVA. Significant differences between parameters before and after L-NAME were assessed using paired t tests. When comparing repeated measurements, we used the Bonferroni correction for performing multiple comparisons. The P<.05 level was considered significant.
Results
All animals were in good health at the time of study. Room air arterial blood gases were pH 7.37±0.01 (±SEM); Pco2, 34±1 mm Hg; and Po2, 88±1 mm Hg. Hematocrit averaged 36±2%. Resting hemodynamics under control conditions and after L-NAME are summarized in the Table. Measurements of coronary diameter at baseline, after L-NAME, and after nitroglycerin (in the presence of L-NAME) are illustrated in Fig 2. Inhibiting nitric oxide production with L-NAME increased mean aortic pressure. Although heart rate (which was paced) and coronary flow remained unchanged, L-NAME constricted the epicardial coronary artery by 103+80 ,m. Intravenous infusion of nitroglycerin dilated the epicardial artery by 536±88 ,um (17.2+3.3% of the resting value obtained after L-NAME). Effects of L-NAME on AcetylcholineInduced Dilation Fig 3 demonstrates the effects of blocking nitric oxide on receptor-mediated epicardial dilation to systemic administration of acetylcholine. Under control conditions, left atrial infusion of acetylcholine at doses between 5 and 15 ,ug/min caused progressive dilation of the epicardial coronary artery that reached 53+±9% of the maximum response found during nitroglycerin infusion. Heart rate, aortic pressure, and coronary flow did not change significantly with increasing doses of acetylcholine (repeated-measures ANOVA). Because coronary flow was not increased, the epicardial dilation represented the direct effects of acetylcholine on the endothelium as opposed to flow-dependent changes. After administration of L-NAME, the epicardial artery dilation to systemic acetylcholine was attenuated at all infusion rates (P<.001, ANOVA) and reached a maximum dilation of 15+6% of the nitroglycerin response at the highest infusion rate (P<.05 versus control response). Thus, in the dose we used, L-NAME attenuated the vasodilation of epicardial conduit arteries to agonist-induced nitric oxide production.
Effect of L-NAME on Reactive Versus Sustained Vasodilation Fig 4 summarizes the effects of L-NAME on reactive hyperemia and reactive epicardial coronary dilation in all of the animals studied. Although L-NAME reduced peak reactive hyperemic flow by a small amount (19+6%, P<.01, L-NAME versus control), it had a much more pronounced effect on the percentage of flow repayment to flow debt, which decreased to 55+7% of the control response (P<.01, L-NAME versus control). The reduction in the volume of the reactive hyperemic response produced by inhibiting nitric oxide production was associated with an attenuation in the peak reactive epicardial arterial dilation to 47±11% of control values (P<.01).
In contrast to the attenuation of reactive dilation by L-NAME, the epicardial diameter change to sustained increases in flow produced by infusing adenosine into the distal coronary artery was not affected (Fig 5) . L-NAME did not affect heart rate (94±6 versus 90±6 beats per minute, P=NS), resting coronary flow (42±4 versus 41±3 mL/min after L-NAME, P=NS), or the increase in mean flow during intracoronary adenosine infusion into the distal circumflex artery (180±21 versus 177±24 mL/min after L-NAME, P=NS). Similarly, changes in epicardial coronary diameter (Fig 5) to sustained adenosine infusion under control conditions (284±36 ,m) were similar to those obtained after inhibiting nitric oxide production (294±67 ,um, P=NS).
There were no significant effects of intracoronary adenosine on arterial pressure. To exclude the possibility that recirculation of adenosine infused into the distal coronary artery could have had direct effects on coronary flow and epicardial coronary artery diameter, we infused adenosine into the pulmonary artery in five animals. During pulmonary artery infusion of adenosine (0.5 mg/min), both coronary flow (45 ±6 mL/min under control conditions versus 48±7 mL/min during adenosine, P=NS) and epicardial coronary diameter (3110±390 ,um under control conditions versus 3120±390 ,um after adenosine, P=NS) were similar. Thus, the rapid metabolism of adenosine by both the pulmonary endothelium and red blood cells reduced arterial concentrations below those that could affect coronary flow and epicardial diameter directly.
Diameter changes during distal vasodilation with restricted coronary flow were evaluated in four animals. There was no effect of L-NAME on resting heart rate (87±4 versus 89±5 beats per minute after L-NAME, P=NS) or coronary flow (42±4 versus 41±4 mL/min after L-NAME, P=NS). During pacing, heart rate (196±5 versus 193±5 beats per minute after L-NAME) and coronary flow (78±9 versus 75±9 mIV/min after L-NAME) increased to the same extent. Pacing-induced increases in coronary flow were modest in relation to maximal flows recruited by intracoronary adenosine in- Nw-nitro-L-arginine methyl ester (L-NAME) on peak epicardial dilation and the reactive hyperemic flow response to a 30-second coronary occlusion. Both diameter changes during reactive epicardial dilation (AD, left) and the reactive hyperemic flow response were attenuated by L-NAME. Peak reactive hyperemic flow (right) as well as the percentage of flow repayment to flow debt (middle) were significantly reduced. Thus, the attenuation of the reactive dilation by L-NAME was, in part, secondary to the attenuation of the flow response. Values are given as mean±SEM.
Peak Flow fusion and peak ischemic vasodilation during reactive hyperemia. Nevertheless, the change in coronary artery diameter we found to a twofold increase in flow produced by pacing under control conditions approached that found when flow was increased fourfold by intracoronary adenosine (170±27 ,um during pacing versus 264±36 ,um during adenosine). After L-NAME, the diameter change to a similar increase in heart rate and flow was markedly attenuated, although not completely abolished (54±22 gm, P<.01 versus control, Fig 6) .
Discussion
The major new finding of our study is that the dilation of epicardial coronary conduit arteries to sustained increases in mean flow at a constant heart rate is not mediated by endothelial nitric oxide production. Nevertheless, inhibiting nitric oxide attenuated the epicardial coronary dilation to pacing-induced increases in flow. The latter finding suggests that nitric oxide production plays an important role in modulating epicardial conduit artery tone in response to changes in coronary flow pulse frequency.
Methodological Limitations
The interpretation of our results is dependent on demonstrating that we inhibited nitric oxide production. We chose the L-arginine analog L-NAME because previous studies have shown it to be a potent inhibitor of nitric oxide synthase.17 Inhibition of receptor-mediated nitric oxide production was confirmed by demonstrating that the dose of L-NAME that was used inhibited acetylcholine-induced dilation in the large epicardial artery. In concert with findings in a variety of other preparations, however, L-NAME did not completely abolish the epicardial vasodilation to acetylcholine. This suggests that additional mechanisms, such as endothelium-dependent hyperpolarization of vascular smooth muscle, may also be involved in eliciting relaxation to this endothelium-dependent agonist.
In a previous study, we demonstrated that this dose of L-NAME attenuated the vasodilation of resistance vessels during intracoronary infusion of acetylcholine at concentrations that were on the plateau of the normal dose-response curve (estimated plasma concentrations, Bar graph of effects of N@-nitro-L-arginine methyl ester (L-NAME) on the change in coronary artery diameter (AD, left) and flow (right) during sustained vasodilation produced by intracoronary adenosine infusion. Maximal flow during adenosine under control conditions was similar to that after L-NAME. The peak coronary diameter change to sustained increases in flow under control conditions was not signfficantly different from the diameter change observed after L-NAME. Thus, nitric oxide production was not re- ,ug/min corresponding to an estimated coronary acetylcholine plasma concentration of 0.0033 ,ug/mL, or approximately 2x iO-mol/L) did not cause significant coronary vasodilation. This is twice as high as the maximum estimated plasma concentration during left atrial infusion that we used in the present study (range, 0.0005 to 0.0015 ,ug/mL assuming a resting cardiac output of 3 L/min). Thus, we were able to dissociate effects of acetylcholine that were directly related to agonist stimulation from those that were secondary to flow. Although this suggests a differential sensitivity of epicardial conduit arteries to the effects of acetylcholine, the dissociation between diameter changes and flow could also have been due to other factors. First, a reduction in the acetylcholine concentration to which the resistance vessels were subjected could have occurred through metabolism by plasma acetylcholinesterase. Alternatively, autoregulatory resistance adjustments in portions of the microcirculation less responsive to the dilator actions of low concentrations of acetylcholine could have kept flow constant.
Although it is clear that adenosine can dilate the epicardial coronary artery secondary to flow-mediated vasodilation, its direct effects are controversial. Hintze and Vatner18 showed that the epicardial dilation to systemic infusion of adenosine was attenuated but not completely abolished by restricting coronary flow. They found that intravenous adenosine increased cross-sectional area of the epicardial artery by 28%. When FIG 6 . Bar graph of effects of Nw-nitro-L-arginine methyl ester (L-NAME) on pacing-induced increases in epicardial coronary diameter (AD, left) and coronary flow (right). There was no effect of L-NAME on the mean coronary flow response when heart rate was increased to -200 beats per minute. Nevertheless, inhibition of nitric oxide markedly attenuated the epicardial artery dilation to pacing. These results suggest that epicardial arterial dilation to increases in pulse frequency are largely dependent on nitric oxide production. Values are given as mean±SEM (n=8).
epicardial dilation always occurred 10 to 15 seconds after coronary flow increased (Fig 1, bottom) , which was the same time delay we found for the epicardial dilation during reactive hyperemia (Fig 1, top) . Finally, we also demonstrated that adenosine infused at this rate was metabolized before recirculating to the systemic circulation because pulmonary artery infusion of adenosine did not increase coronary flow or dilate the epicardial coronary artery. These considerations substantiate our conclusion that the epicardial vasodilation we observed was mediated by changes in flow and not secondary to direct effects of adenosine on the epicardial coronary artery.
Contrasting Effects of L-NAME on Epicardial Dilation to Reactive Hyperemia Versus Sustained Increases in Flow
Reactive epicardial coronary dilation after a 30-second coronary occlusion was attenuated by L-NAME to a degree that was similar to the responses previously reported in conscious dogs with L-NMMA by Chu et al. 10 In contrast to their study, however, we found that both peak reactive hyperemic flow and the percentage of flow repayment to flow debt were significantly reduced. When flow was increased by infusing adenosine into the distal coronary circulation, the epicardial dilation to a sustained increase in mean flow was not affected. These findings suggest that the dilation to changes in mean coronary flow was elicited by mechanisms that were not dependent on nitric oxide production. They support the notion that the attenuation of reactive epicardial dilation by L-NAME was most likely secondary to changes in the volume or duration of the reactive hyperemic flow response. Although our interpretation differs from that of Chu et al, their inability to detect significant effects of L-NMMA on reactive hyperemia may have been related to the statistical power of their data, which was limited by a small sample size (n=4). In this regard, it is important to point out that although they did not quantify the percentage of flow repayment to flow debt, they did observe a trend for L-NMMA to reduce peak hyperemic flow. We, as well as others, have consistently found that L-arginine analogs attenuate the coronary reactive hyperemic response. '5,20,2' In contrast to the lack of effect of L-NAME on flow-mediated vasodilation in epicardial conduit arteries in our study, Kuo et a19 have shown that flowmediated vasodilation in isolated subepicardial porcine arterioles (-80 gm resting diameter) is abolished by inhibiting nitric oxide production with L-NMMA. Flowmediated vasodilation produced substantially larger changes in the diameter of resistance arterioles (p:30% of resting diameter) than we found in epicardial conduit arteries (:5% to 10% of resting diameter). In addition, like the more rapid time course of the coronary reactive hyperemic flow response, flow-mediated changes in arteriolar caliber appeared to reach steady state much more rapidly (10 to 30 seconds, see Fig 4, Reference 8 ) than flow-mediated vasodilation of epicardial conduit arteries, which peaked after 60 seconds and lasted 5 to 10 minutes (Fig 1, top) . A number of studies have demonstrated differential responses of coronary conduit and resistance vessels to pharmacological stimuli such as thrombin, vasopressin, and nitrates.2223 The difference in transient and steady-state diameter responses to increased flow in arteriolar and epicardial arteries suggests that the mechanisms responsible for flow-mediated vasodilation in each class of vessel are also different, with nitric oxide-dependent mechanisms predominating in coronary resistance vessels.
A limited number of in vivo studies have examined the effects of sustained increases in mean flow on the diameter of conduit arteries in other vascular beds in acutely instrumented anesthetized animals. Kaiser et a124 found that the femoral artery dilated to increased flow and that this dilation could be attenuated by applying topical methylene blue. This can inactivate guanylate cyclase as well as bind nitric oxide. The former mechanism appears to be the most important because they could not reverse the inhibition of methylene blue by suffusing the vessel with buffer. Although their results are compatible with the notion that changes in steady flow dilated the femoral artery by increasing cyclic GMP (cGMP) (presumably through increased nitric oxide production), the flow variations were produced by varying the speed of a roller pump. As a result, effects of pulse frequency could not be excluded and were also accentuated as the speed and flow rate through the pump were increased. In the cerebral circulation, Fujii et al"l increased basilar artery flow using unilateral and bilateral carotid occlusion in anesthetized rats. They found that basilar artery dilation (resting diameter, :250 ,m) to sustained increases in flow was not affected by topical application of a variety of antagonists, including L-NMMA in a preparation in which changes in pulse frequency appear to have been minimal. Our results with L-NAME are similar to the findings of Fujii et al and indicate that changes in coronary diameter as steady flow is varied at a constant heart rate (ie, constant pulse frequency) are also not dependent on nitric oxide production in the coronary circulation of In concert with these in vitro studies, we also found that changes in pulse frequency had an effect on large coronary artery tone in conscious dogs that was dependent on nitric oxide production. Macho et a129 previously found that pacing-induced increases in flow produced vasodilation of the large epicardial artery but did not dissociate the role of mean flow and pulse frequency on the responses. In a subsequent study, Hintze and Vatner2 showed that pacing-induced increases in coronary artery diameter continued to occur when mean flow was kept constant by inflating a coronary occluder, indirectly suggesting that pulse frequency affected epicardial tone in the absence of a change in mean flow. Our results also demonstrate that pulse frequency is an important determinant of epicardial tone in conscious dogs. Pacing caused modest but comparable increases in flow before and after L-NAME. Under control conditions, we found that epicardial diameter increased by (Fig 7,  hatched circles) . There are several alternative explanations for the disparity in the effects of inhibiting nitric oxide production on epicardial artery dilation to pacing and intracoronary infusion of adenosine. Although previous studies have suggested that the coronary flow-diameter relation is linear, the effects of inhibiting nitric oxide production on the relation are unknown. Conceivably, high levels of flow may be able to overcome the blockade of nitric oxide production produced by L-NAME in a dose-dependent fashion, whereas lower levels of mean flow, such as those encountered during pacing, cannot. Flow-diameter relations performed over a wide range of flow will be required to address this question. Another possibility is that adenosine dilates the epicardial artery through propagated responses from distal to more proximal vessels. Making this less likely, however, is the finding that conduit artery vasodilation continues to occur normally after transecting vessels from the distal vascular bed130 as well as the lack of an effect of adenosine on coronary resistance vessels > 150 gm from in vivo microcirculatory studies. 31 Finally, although we have interpreted the inhibition of epicardial dilation during pacing to indicate a coupling of nitric oxide production to pulse frequency, other components of the pulsatile waveform, including pulse amplitude and the rate of change in flow, are altered when mean coronary flow is varied in vivo. Perfusion of isolated coronary conduit vessels with more controlled flow and pressure waveforms will be required to elucidate whether any of these factors are involved in eliciting flow-mediated vasodilation.
While our results indicate that nitric oxide production is not required for flow-mediated vasodilation of epicardial conduit arteries, we did not define the other mediators that may be responsible for these responses. They are probably produced by the endothelium in light of previous in vivo studies that demonstrate that flowmediated effects are abolished by denuding the endothelium in vitro25 as well as in epicardial arteries in conscious dogs in vivo.6 Although prostaglandins may affect basal tone, previous studies have shown that they are unlikely to be involved in epicardial artery dilation to changes in flow.3 In addition, all of the animals in our study chronically received aspirin to maintain patency of the catheters. Several laboratories have demonstrated that a soluble hyperpolarizing factor (endotheliumderived hyperpolarizing factor) is released in response to a variety of endothelium-dependent agonists.32,33 While this factor has not been identified, it could explain the persistent epicardial artery dilation we observed to sustained increases in mean coronary flow as well as the residual vasodilation we observed to acetylcholine after inhibiting nitric oxide production. Another possibility is that epicardial vasodilation to sustained changes in mean flow is mediated by direct hyperpolarization of the endothelial cell by luminal shear stress. 34 This mechanism has been demonstrated in cultured endothelial cells, but its importance in vivo remains to be defined.
In summary, the role of nitric oxide in mediating epicardial conduit artery dilation to changes in flow is complex and appears to differ from that observed in coronary resistance vessels. Vasodilation of large epicardial arteries to sustained as opposed to transient changes in flow is not dependent on nitric oxide production. Nevertheless, dilation to changes in pulse frequency appears to be mediated by nitric oxide because it is inhibited by the arginine analog L-NAME. Under some circumstances, the epicardial artery dilation to changes in pulse frequency appears to be quantitatively similar to that resulting from large increases in mean flow. This may have particular significance in the coronary circulation due to the systolic-diastolic variations in epicardial flow. Based on our findings, future studies designed to determine the mechanisms responsible for flow-mediated vasodilation will need to carefully control and characterize mean flow as well as flow pulse frequency.
